skip to main content

SciTech ConnectSciTech Connect

Title: Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis

Anti-angiogenic therapy has been recognized as a powerful potential strategy for impeding the growth of various tumors. However no major therapeutic effects have been observed to date, mainly because of the emergence of several resistance mechanisms. Among novel strategies to target tumor vasculature, some oncolytic viruses open up new prospects. In this context, we addressed the question whether the rodent parvovirus H-1PV can target endothelial cells. We show that cultures of human normal (HUVEC) and immortalized (KS-IMM) endothelial cells sustain an abortive viral cycle upon infection with H-1PV and are sensitive to H-1PV cytotoxicity. H-1PV significantly inhibits infected KS-IMM tumor growth. This effect may be traced back by the virus ability to both kill proliferating endothelial cells and inhibit VEGF production Recombinant H-1PV vectors can also transduce tumor cells with chemokines endowed with anti-angiogenesis properties, and warrant further validation for the treatment of highly vascularized tumors. - Highlights: • The oncolytic parvovirus H-1PV can target endothelial cells. • Abortive viral cycle upon infection of endothelial cells with H-1PV. • Inhibition of VEGF expression and KS-IMM tumor growth by H-1PV.
Authors:
 [1] ;  [2] ; ;  [1] ;  [2] ;  [1]
  1. Tumor Virology Division, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg (Germany)
  2. Laboratory of Molecular Immunology, Rega Institute for Medical Research, K.U. Leuven, Leuven (Belgium)
Publication Date:
OSTI Identifier:
22436665
Resource Type:
Journal Article
Resource Relation:
Journal Name: Virology; Journal Volume: 447; Journal Issue: 1-2; Other Information: Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; ANGIOGENESIS; CAPACITY; RODENTS; SARCOMAS; THERAPY; TOXICITY; TUMOR CELLS; VALIDATION; VIRUSES